Acadian Asset Management’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-1,339,331
| Closed | -$1.15M | – | 1849 |
|
|
2023
Q4 | $1.15M | Buy |
1,339,331
+145,360
| +12% | +$125K | ﹤0.01% | 820 |
|
|
2023
Q3 | $1.28M | Buy |
1,193,971
+55,128
| +5% | +$58.9K | 0.01% | 805 |
|
|
2023
Q2 | $2.95M | Buy |
1,138,843
+200,409
| +21% | +$519K | 0.01% | 598 |
|
|
2023
Q1 | $3.82M | Buy |
938,434
+357,211
| +61% | +$1.46M | 0.02% | 525 |
|
|
2022
Q4 | $2.91M | Buy |
+581,223
| New | +$2.91M | 0.01% | 580 |
|
|
2022
Q3 | – | Sell |
-16,716
| Closed | -$214K | – | 1896 |
|
|
2022
Q2 | $214K | Buy |
16,716
+1,563
| +10% | +$20K | ﹤0.01% | 1179 |
|
|
2022
Q1 | $230K | Buy |
15,153
+13,413
| +771% | +$204K | ﹤0.01% | 1178 |
|
|
2021
Q4 | $30K | Buy |
+1,740
| New | +$30K | ﹤0.01% | 1561 |
|
|
2021
Q3 | – | Sell |
-4,305
| Closed | -$85K | – | 2086 |
|
|
2021
Q2 | $85K | Buy |
+4,305
| New | +$85K | ﹤0.01% | 1675 |
|
|
2020
Q3 | – | Sell |
-9,452
| Closed | -$186K | – | 2403 |
|
|
2020
Q2 | $186K | Buy |
9,452
+4,109
| +77% | +$80.9K | ﹤0.01% | 1521 |
|
|
2020
Q1 | $66K | Buy |
+5,343
| New | +$66K | ﹤0.01% | 1450 |
|